Solithromycin - Melinta Therapeutics

Drug Profile

Solithromycin - Melinta Therapeutics

Alternative Names: CEM-101; OP-1068; T-4288

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; Melinta Therapeutics; Toyama Chemical
  • Class Anti-infectives; Antibacterials; Antimalarials; Heterocyclic bicyclo compounds; Ketolides; Macrolides; Oxazoles; Pyrans; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia
  • Phase III Bronchitis; Chlamydial infections; Gonorrhoea; Otorhinolaryngological infections; Respiratory tract infections; Sinusitis; Urethritis
  • Phase II Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis
  • Preclinical Eye-Disorders
  • No development reported Anthrax; Bacterial infections; Cystic fibrosis; Enterococcal infections; Legionella infections; Malaria; Mycobacterium avium complex infections; Mycoplasma infections; Obstetric and gynaecological infections; Otitis media; Tularaemia

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Otitis-media in USA
  • 29 May 2018 Cempra terminates a phase II/III trial due to development not proceeding in Community-acquired pneumonia (In adolescents, In children, In infants) in USA, United Kingdom, Philippines, Bulgaria, Spain, Hungary (IV) (NCT02605122)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Bacterial-infections(Adjunctive treatment, In adolescents, In children, In infants, In neonates) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top